Nerve conduction is now a measured endpoint in controlled stem cell trials.
Peripheral neuropathy, most commonly from diabetes, is one of the harder problems in medicine because conventional drugs manage symptoms rather than the nerve itself. That is exactly why cell therapy is being studied here, and the early controlled data is measurable rather than anecdotal.
This page covers what those trials report, how early this field genuinely is, and what a proper review of your case examines.
Aurenza does not claim that regenerative medicine treats or reverses neuropathy of any kind.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What the Research Shows
Peripheral neuropathy, most commonly from diabetes, is one of medicine's harder problems because conventional drugs manage symptoms rather than the nerve. That is exactly why cell therapy is being studied here, and the controlled data measures something objective: electrical conduction in the nerve itself.
A 2024 systematic review and meta-analysis in Stem Cell Research and Therapy screened more than 5,400 records and pooled seven controlled human trials of cell therapy in diabetic peripheral neuropathy, using bone marrow mononuclear cells and umbilical cord MSCs delivered mainly by intramuscular injection. The pooled result: motor nerve conduction velocity improved by a weighted mean difference of 2.2 meters per second, with sensory conduction also significantly improved, and the full analysis additionally examined vibration perception thresholds and Toronto Clinical Scoring System outcomes. Nerve conduction velocity is not a feeling or a survey answer; it is a measurement.
Underneath the human work sits a deep preclinical base: a 2025 systematic review of 29 animal studies in Neuroscience reported consistent improvements in nerve conduction, muscle action potentials, and nerve blood flow, and a companion meta-analysis of preclinical MSC studies found the same pattern across models.
The Honest Line
Seven controlled human trials is a real evidence base and a small one, with different cell types, doses, and follow-up lengths across studies. No large, multi-site, placebo-controlled trial has yet shown durable improvement in daily function and pain across years, and no study shows a guarantee it works every time, or that it will work for you. One more thing an honest page must say: the controlled research is almost entirely in diabetic neuropathy, and evidence in one cause does not automatically transfer to another. Some neuropathies trace to reversible drivers, and finding one of those in a workup is worth more than any procedure.
Why This Is Exactly Where a Candidacy Review Comes In
The cause of your neuropathy, the completeness of your workup, and your metabolic control decide whether the research above describes you at all, which is precisely what gets established first. Every trial above produced its results in selected patients who met specific criteria. That is the gap between "documented in research" and "right for you," and it is the gap a candidacy review exists to close. Before anything is recommended, your bloodwork, biomarkers, imaging, and history are reviewed by a physician panel to establish whether you are actually in the population the research describes. If the picture supports moving forward, you will know exactly why. If it does not, you will be told that, plainly. That is where to start.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
What Your Candidacy Review Covers
- The documented cause of your neuropathy, including your diagnostic workup and whether it is complete.
- Your metabolic control, since glucose management is the foundation any diabetic neuropathy discussion sits on.
- Nerve conduction studies where available, which establish an objective baseline.
- Your medication history and symptom pattern, including what has and has not helped.
- Your bloodwork and biomarker panel, reviewed by a physician panel with specialist input where the case calls for it.
What to Ask Any Provider
What do you believe is causing my neuropathy, and is my workup complete? Which controlled trials are you relying on, and did they study my type of neuropathy? What is being administered, by what route, at what verified cell count? How will change be measured objectively rather than by impression? What would make me a poor candidate?
The Honest Limits
Individual results cannot be predicted or guaranteed. These applications are not FDA approved for neuropathy, and the procedure takes place in Mexico under COFEPRIS regulation. Continue working with your existing providers on glucose control and symptom management, and seek prompt evaluation for rapidly progressing weakness or new loss of function.
Free consultation with a care consultant, many of our care consultants are registered nurses. No sales reps. No receptionist.
Free consultation with a care consultant, many of whom are registered nurses. No sales reps. No receptionist.